Search research articles
Contact Us
Filters
Showing results (201-210 of 264) with videos related to
Page
of 27
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 4, 2023
MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC
Naoki Haratake, Hiroki Ozawa, Yoshihiro Morimoto, et al.
Signal Transduction and Targeted Therapy
|
November 27, 2025
MUCIN 1 confers inflammatory memory of tyrosine kinase inhibitor resistance in non-small cell lung cancer
Shinkichi Takamori, Naoki Haratake, Atrayee Bhattacharya, et al.
Biorxiv : the Preprint Server for Biology
|
August 12, 2025
Suppression of PP2A-B56α Drives EMT in EGFR Mutant Non-Small Cell Lung Cancer
Brittany N Heil, Garima Baral, Claire M Pfeffer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 5, 2021
A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor
Ibiayi Dagogo-Jack, Philicia Moonsamy, Justin F Gainor, et al.
Science Translational Medicine
|
August 2, 2013
TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma
Ryan B Corcoran, Stephen Michael Rothenberg, Aaron N Hata, et al.
Cancer Research Communications
|
August 23, 2024
Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer
Takahiko Murayama, Navin R Mahadevan, Catherine B Meador, et al.
Science Translational Medicine
|
March 30, 2022
Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells
Moiez Ali, Min Lu, Hazel Xiaohui Ang, et al.
Oncogene
|
April 11, 2026
Suppression of PP2A-B56α drives EMT in EGFR mutant non-small cell lung cancer
Brittany N Heil, Garima Baral, Claire M Pfeffer, et al.
Nature Communications
|
August 11, 2019
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
Ryohei Katayama, Bo Gong, Noriko Togashi, et al.
JCO Precision Oncology
|
January 16, 2018
Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in <i>ROS1</i>-Positive Non-Small-Cell Lung Cancer
Justin F Gainor, Diane Tseng, Satoshi Yoda, et al.
Page
of 27
Search research articles
Search
Showing results (201-210 of 264) with videos related to
Sort By:
Page
of 27
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 4, 2023
MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC
Naoki Haratake, Hiroki Ozawa, Yoshihiro Morimoto, et al.
Signal Transduction and Targeted Therapy
|
November 27, 2025
MUCIN 1 confers inflammatory memory of tyrosine kinase inhibitor resistance in non-small cell lung cancer
Shinkichi Takamori, Naoki Haratake, Atrayee Bhattacharya, et al.
Biorxiv : the Preprint Server for Biology
|
August 12, 2025
Suppression of PP2A-B56α Drives EMT in EGFR Mutant Non-Small Cell Lung Cancer
Brittany N Heil, Garima Baral, Claire M Pfeffer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 5, 2021
A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor
Ibiayi Dagogo-Jack, Philicia Moonsamy, Justin F Gainor, et al.
Science Translational Medicine
|
August 2, 2013
TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma
Ryan B Corcoran, Stephen Michael Rothenberg, Aaron N Hata, et al.
Cancer Research Communications
|
August 23, 2024
Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer
Takahiko Murayama, Navin R Mahadevan, Catherine B Meador, et al.
Science Translational Medicine
|
March 30, 2022
Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells
Moiez Ali, Min Lu, Hazel Xiaohui Ang, et al.
Oncogene
|
April 11, 2026
Suppression of PP2A-B56α drives EMT in EGFR mutant non-small cell lung cancer
Brittany N Heil, Garima Baral, Claire M Pfeffer, et al.
Nature Communications
|
August 11, 2019
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
Ryohei Katayama, Bo Gong, Noriko Togashi, et al.
JCO Precision Oncology
|
January 16, 2018
Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in <i>ROS1</i>-Positive Non-Small-Cell Lung Cancer
Justin F Gainor, Diane Tseng, Satoshi Yoda, et al.
Page
of 27